Radiogenomics is a powerful method for studying the biology of GBM, which has demonstrated its ability to characterize GBM, to predict molecular signature (in particular the status of the MGMT promoter methylation and IDH mutation) and to determine therapeutic response and survival of newly diagnosed patients. The gene discussed is MGMT; the disease is glioblastoma.